Methotrexate for Central Serous Chorioretinopathy Treatment Trial
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Central serous chorioretinopathy (CSC) is a disease of unknown origin however multiple
reports have indicated correlation of appearance of CSC with exposure to exogenous or
elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids
is upregulated in many inflammatory conditions, control of the inflammation may be beneficial
in reducing this level thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely
used to control different types of inflammation. The investigators are going to try an
escalating doses of MTX to treat CSC under full medical supervision.